Glucotrack, Inc. · NASDAQ:GCTK
Glucotrack — Integrity Applications — Investor Presentation (October 2017)
16 slides from Glucotrack's investor presentation, Oct 5, 2017
Slide 1: GlucoTrack: A First In Class Non-Invasive Glucose Monitoring Platform
GlucoTrackA First In Class Non-Invasive GlucoseMonitoring Platform Digital Health SolutionSupporting healthy behaviors by providingindividual context to glucose data The Integrity Applications Growth Story Attractive Industry Dynamics Glucose monitoring undergoing rapid disruptive change
Slide 2: Forward-Looking Statements
Forward-Looking Statements This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Statements contained in this presentation that are not statements of historical fact may be deemed to be forward-looking statements. Without li
Slide 3: Executive Summary
Unique product , solid clinical dataFirst -in-class non-invasive glucose monitorUnique “triple-sensor” technology combined with proprietary algorithm provides unmatched accuracyApproved for use in T2 and pre-diabetes patients in Europe and AsiaMultiple clinical trials in over 1000 patients Attractiv
Slide 4: Attractive Industry Segment with Strong Market Dynamics
Attractive Industry Segment with Strong Market Dynamics Health/Wellness1B At Risk250M Pre-Diabetes318M Diabetes (T1/T2)415M Population High performance individualsHealth and WellnessHigh stress professions Obese (BMI > 25kg/m2Genetic risk of diabetesHigh risk pregnancy HbA1C 5.7%-6.4%BMI >25kg/m2Add
Slide 5: Glucose Measurement is Undergoing a Major Transformation
Glucose Measurement is Undergoing a Major Transformation Commercial Monitor only R&D Stage of Development IntegratedSolution Digital HealthProductSolution Google/Novartis GlucoWise (Mediwise) Cnoga Medical Symphony (Echo Tx) Noviosense Medella Health Light Touch Medical GlucoVista Sano GlucoTrack K’
Slide 6: GlucoTrack: A Unique Non-Invasive Glucose Monitoring Solution
Eliminates daily finger pricksSimple calibration with ear clip replacement once every six months Cost-effectiveUnlimited testingLess than cost of conventional glucose monitoring Verified algorithm for estimated HBA1CTrend data allows individual monitoring over time GlucoTrackA Unique Non-Invasive Gl
Slide 7: GlucoTrack's Novel Triple-Sensor Technology
Ultrasonic Sound velocity through tissue varies with glucose concentration Electromagnetic Tissue impedance changes with glucose concentration. thermal Heat transfer characteristics of tissue vary with glucose concentration. GlucoTrack’s Novel Triple-Sensor Technology The three independent readings
Slide 8: Most Recent Clinical Study Demonstrated 17% MARD
T2 Consensus Error Grid Zones Number of Points Percentage A+B 304 99.4% A 277 90.2 B 27 9.2 C 1 0.3 D 0 0.0 E 0 0.0 Total 305 100.0 Most Recent Clinical Study Demonstrated 17% MARD and 99.4% of measurements within A+B Zones Type 2 Consensus Error Grid (CEG) Sources: Pfutzner Science & Health Institu
Slide 9: Recent Clinical Trials Demonstrate Reliable Accuracy
Recent Clinical Trials Demonstrate Reliable Accuracy Objective Patient Number Invasive Reference Accuracy of GlucoTrack DF-F device 44 HemoCue Demonstrate ear-clip performance over 6 months 18 HemoCue Accuracy as a function of differing demographics, age, gender, BMI, HbA1c, medication 132 HemoCue S
Slide 10: Transforming Integrity
Transforming Integrity Management & Talent Structure & Process Commercial Mindset Product Portfolio Distribution Partners US Focus Integrity in 2016 Where will we be in 2018? Significant Talent GapLack of commercial experience World class managementTrack record in commercialization & diabetes Lack o
Slide 11: Global Executive Team
Global Executive Team John GrahamCEO and Chairman Senior executive positions at Sanofi Aventis Pharma, Genzyme Corporation, Menarini Group and Ernst & Young; CEO at Invida Pharmaceuticals Sami Sassoun, CPA, USA, BACFO Previously with Bedrock Enterprises, Brean Murray, Cohn Reznick David PodwalskiChi
Slide 12: Commercialization
Commercialization Commencement of phased product launch in EuropeImproved distributor selectionTransformed sales modelReset pricing and reimbursementBuild patient and HCP advocacyExpand clinical evidenceImplement Digital Health Applications
Slide 13: Product Strategy
DIGITAL HEALTH SOLUTIONS GlucoTrack app and integration with digital health solutions and health monitoring devices Accuracy & HUMAN FACTORS Reduce calibration, smaller handset, algorithm modifications based on real world use MINIATURIZATION & SCALE Wireless earclip, manufacturing transition to part
Slide 14: Integrity Growth Strategy
Integrity Growth Strategy Digital Health Solutions Create Multiple White Space Opportunities Glucose MonitoringTechnology Platform Glucose MonitoringProduct Solutions Existing Business Adjacent Business White Space Value $ Disease & WellnessManagement 2017 2020 2022+ GlucoTrack Pro Private label/lic
Slide 15: Future GlucoTrack Wireless
FutureGlucoTrack Wireless Wireless ear clip App tailored to maximize healthy patient behaviors
Slide 16: Recap of the Story
Recap of the Story Attractive industry dynamicsUnique product with strong clinical dataTransformation underway with near-term tangible resultsCurrently at an inflection point in commercializationUnder-managed and under-invested in the past with upside potentialStrong technology with significant oppo
Integrity Applications — Investor Presentation (October 2017) on 6ix